{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:12:55Z","timestamp":1793776375950,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,5,6]],"date-time":"2011-05-06T00:00:00Z","timestamp":1304640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00259-011-1821-1","type":"journal-article","created":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T13:19:51Z","timestamp":1304601591000},"page":"1702-1714","source":"Crossref","is-referenced-by-count":92,"title":["Individualized quantification of brain \u03b2-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer\u2019s disease and healthy controls"],"prefix":"10.1007","volume":"38","author":[{"given":"Henryk","family":"Barthel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Luthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Patt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hammerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birk","family":"Eggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schildan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swen","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Reischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann-Josef","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Reininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,6]]},"reference":[{"key":"1821_CR1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14728220902865614","volume":"13","author":"A Tarditi","year":"2009","unstructured":"Tarditi A, Caricasole A, Terstappen G. Therapeutic targets for Alzheimer\u2019s disease. Expert Opin Ther Targets 2009;13:551\u201367.","journal-title":"Expert Opin Ther Targets"},{"key":"1821_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1474-4422(09)70332-1","volume":"9","author":"BA Bergmans","year":"2010","unstructured":"Bergmans BA, De Strooper B. Gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol 2010;9:215\u201326.","journal-title":"Lancet Neurol"},{"key":"1821_CR3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/156720509790147151","volume":"6","author":"P Taupin","year":"2009","unstructured":"Taupin P. Adult neurogenesis, neural stem cells and Alzheimer\u2019s disease: developments, limitations, problems and promises. Curr Alzheimer Res 2009;6:461\u201370.","journal-title":"Curr Alzheimer Res"},{"key":"1821_CR4","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer Report 2009. http:\/\/www.alz.co.uk\/research\/worldreport ."},{"key":"1821_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"1821_CR6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jalz.2009.09.002","volume":"5","author":"S Gauthier","year":"2009","unstructured":"Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer\u2019s disease? Alzheimers Dement 2009;5:489\u201391.","journal-title":"Alzheimers Dement"},{"key":"1821_CR7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1348\/174866407X227015","volume":"2","author":"KE Pike","year":"2008","unstructured":"Pike KE, Savage G. Memory profiling in mild cognitive impairment: can we determine risk for Alzheimer\u2019s disease? J Neuropsychol 2008;2:361\u201372.","journal-title":"J Neuropsychol"},{"key":"1821_CR8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1212\/WNL.40.9.1364","volume":"40","author":"WA Kukull","year":"1990","unstructured":"Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby MS, Hughes JP. The validity of 3 clinical diagnostic criteria for Alzheimer\u2019s disease. Neurology 1990;40:1364\u20139.","journal-title":"Neurology"},{"key":"1821_CR9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0022-510X(90)90072-U","volume":"95","author":"K Jellinger","year":"1990","unstructured":"Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 1990;95:239\u201358.","journal-title":"J Neurol Sci"},{"key":"1821_CR10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734\u201346.","journal-title":"Lancet Neurol"},{"key":"1821_CR11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"1821_CR12","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412\u20134.","journal-title":"Neurology"},{"key":"1821_CR13","first-page":"143","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association; 1994. p. 143\u20137. DSM-IV.","edition":"4"},{"key":"1821_CR14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"1821_CR15","first-page":"641","volume":"24","author":"JC Morris","year":"1988","unstructured":"Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer\u2019s disease (CERAD) clinical and neuropsychological assessment of Alzheimer\u2019s disease. Psychopharmacol Bull 1988;24:641\u201352.","journal-title":"Psychopharmacol Bull"},{"key":"1821_CR16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1532-5415.1989.tb02234.x","volume":"37","author":"GP Wolf-Klein","year":"1989","unstructured":"Wolf-Klein GP, Silverstone FA, Levy AP, Brod MS. Screening for Alzheimer\u2019s disease by clock drawing. J Am Geriatr Soc 1989;37:730\u20134.","journal-title":"J Am Geriatr Soc"},{"key":"1821_CR17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.nucmedbio.2005.06.001","volume":"32","author":"W Zhang","year":"2005","unstructured":"Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol 2005;32:799\u2013809.","journal-title":"Nucl Med Biol"},{"key":"1821_CR18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10967-010-0514-8","volume":"284","author":"M Patt","year":"2010","unstructured":"Patt M, Schildan A, Barthel H, Becker G, Schultze-Mosgau MH, Rohde B, et al. Metabolite analysis of [18F]florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. J Radioanaly Nucl Chem 2010;284:557\u201362.","journal-title":"J Radioanaly Nucl Chem"},{"key":"1821_CR19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/archgenpsychiatry.2009.106","volume":"66","author":"PM Meyer","year":"2009","unstructured":"Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, et al. Reduced \u03b14\u03b22*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009;66:866\u201377.","journal-title":"Arch Gen Psychiatry"},{"key":"1821_CR20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neuint.2008.12.016","volume":"54","author":"MM Svedberg","year":"2009","unstructured":"Svedberg MM, Hall H, Hellstr\u00f6m-Lindahl E, Estrada S, Guan Z, Nordberg A, et al. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2009;54:347\u201357.","journal-title":"Neurochem Int"},{"key":"1821_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129\u201335.","journal-title":"Lancet Neurol"},{"key":"1821_CR22","volume-title":"Co-planar stereotaxic atlas of the human brain","author":"J Talairach","year":"1988","unstructured":"Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme; 1988."},{"key":"1821_CR23","volume-title":"Textbook of receptor pharmacology","author":"DG Haylett","year":"2002","unstructured":"Haylett DG. Textbook of receptor pharmacology. Boca Raton: CRC; 2002."},{"key":"1821_CR24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/00029238.1971.11080840","volume":"11","author":"DV Cicchetti","year":"1971","unstructured":"Cicchetti DV, Allison T. New procedure for assessing reliability of scoring EEG sleep recordings. Am J EEG Technol 1971;11:101\u20139.","journal-title":"Am J EEG Technol"},{"key":"1821_CR25","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1073\/pnas.0914141107","volume":"107","author":"L Mosconi","year":"2010","unstructured":"Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 2010;107:5949\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1821_CR26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, N\u00e5gren K, et al. Conversion of amyloid positive and negative MCI to AD over 3\u00a0years: an 11C-PIB PET study. Neurology 2009;73:754\u201360.","journal-title":"Neurology"},{"key":"1821_CR27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"1821_CR28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1212\/01.wnl.0000259035.98480.ed","volume":"68","author":"GD Rabinovici","year":"2007","unstructured":"Rabinovici GD, Furst AJ, O\u2019Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68:1205\u201312.","journal-title":"Neurology"},{"key":"1821_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.drudis.2008.12.004","volume":"14","author":"PW Thompson","year":"2009","unstructured":"Thompson PW, Lockhart A. Monitoring the amyloid beta-peptide in vivo\u2014caveat emptor. Drug Discov Today 2009;14:241\u201351.","journal-title":"Drug Discov Today"},{"key":"1821_CR30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363\u201372.","journal-title":"Lancet Neurol"},{"key":"1821_CR31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2967\/jnumed.108.055756","volume":"50","author":"GJ O\u2019Keefe","year":"2009","unstructured":"O\u2019Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, et al. Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 2009;50:309\u201315.","journal-title":"J Nucl Med"},{"key":"1821_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron 2009;63:287\u2013303.","journal-title":"Neuron"},{"key":"1821_CR33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"CJ Morris","year":"2010","unstructured":"Morris CJ, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122\u201331.","journal-title":"Ann Neurol"},{"key":"1821_CR34","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.278.16.1349","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349\u201356.","journal-title":"JAMA"},{"key":"1821_CR35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0140-6736(93)91709-U","volume":"342","author":"AM Saunders","year":"1993","unstructured":"Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer\u2019s disease and in other amyloid-forming diseases. Lancet 1993;342:710\u20131.","journal-title":"Lancet"},{"key":"1821_CR36","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.0b013e3181a2e8d0","volume":"72","author":"A Drzezga","year":"2009","unstructured":"Drzezga A, Grimmer T, Henriksen G, M\u00fchlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009;72:1487\u201394.","journal-title":"Neurology"},{"key":"1821_CR37","doi-asserted-by":"crossref","unstructured":"Stankoff B, Freeman L, Aigrot MS, Chardain A, Doll\u00e9 F, Williams A, et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(11) C]-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole. Ann Neurol 2010 [Epub ahead of print].","DOI":"10.1002\/ana.22320"},{"key":"1821_CR38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446\u201352.","journal-title":"Neurology"},{"key":"1821_CR39","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718\u201325.","journal-title":"Neurology"},{"key":"1821_CR40","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509\u201317.","journal-title":"Arch Neurol"},{"key":"1821_CR41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC. Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol 1999;45:358\u201368.","journal-title":"Ann Neurol"},{"key":"1821_CR42","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/WNL.0b013e3181bacf1b","volume":"73","author":"NM Scheinin","year":"2009","unstructured":"Scheinin NM, Aalto S, Koikkalainen J, L\u00f6tj\u00f6nen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73:1186\u201392.","journal-title":"Neurology"},{"key":"1821_CR43","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer\u2019s disease. Brain 2007;130:2837\u201344.","journal-title":"Brain"},{"key":"1821_CR44","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","volume":"25","author":"JC Price","year":"2005","unstructured":"Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528\u201347.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1821_CR45","first-page":"1959","volume":"46","author":"BJ Lopresti","year":"2005","unstructured":"Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959\u201372.","journal-title":"J Nucl Med"},{"key":"1821_CR46","doi-asserted-by":"crossref","unstructured":"Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer\u2019s disease. Neurobiol Aging. doi: 10.1016\/j.neurobiolaging.2010.03.011 .","DOI":"10.1016\/j.neurobiolaging.2010.03.011"},{"key":"1821_CR47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1745-7599.2006.00137.x","volume":"18","author":"JR Harvan","year":"2006","unstructured":"Harvan JR, Cotter V. An evaluation of dementia screening in the primary care setting. J Am Acad Nurse Pract 2006;18:351\u201360.","journal-title":"J Am Acad Nurse Pract"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-1821-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-011-1821-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-1821-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T10:50:23Z","timestamp":1560163823000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-011-1821-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,6]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1007\/s00259-011-1821-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,6]]}}}